Use: Labeled indications
- XALATAN is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
Full indications and usage US FDA label
1 INDICATIONS AND USAGE XALATAN is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. XALATAN is a prostaglandin F 2α analogue indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. (1)
Contraindications
4 CONTRAINDICATIONS Known hypersensitivity to latanoprost, benzalkonium chloride, or any other ingredients in this product. Known hypersensitivity to latanoprost, benzalkonium chloride, or any other ingredients in this product. (4)
US FDA labelDosing: Adult
Dosage and administration (US label) US FDA label
2 DOSAGE AND ADMINISTRATION The recommended dosage is one drop in the affected eye(s) once daily in the evening. If one dose is missed, treatment should continue with the next dose as normal. The dosage of XALATAN should not exceed once daily; the combined use of two or more prostaglandins, or prostaglandin analogs including XALATAN is not recommended.
It has been shown that administration of these prostaglandin drug products more than once daily may decrease the IOP lowering effect or cause paradoxical elevations in IOP. Reduction of the IOP starts approximately 3 to 4 hours after administration and the maximum effect is reached after 8 to 12 hours. XALATAN may be used concomitantly with other topical ophthalmic drug products to lower IOP.
In vitro studies have shown that precipitation occurs when eye drops containing thimerosal are mixed with XALATAN. If more than one topical ophthalmic drug is being used, the drugs should be administered at least five (5) minutes apart. Contact lenses should be removed prior to the administration of XALATAN, and may be reinserted 15 minutes after administration.
One drop in the affected eye(s) once daily in the evening. (2)
Dosing: Altered kidney function
No kidney-specific text is available from the US label for this generic yet. Check the Philippine package insert in the products table.
Kidney-specific guidance from renalcarematters.com: in preparation.
Dosing: Pediatric
Pediatric use (US label) US FDA label
8.4 Pediatric Use Safety and effectiveness in pediatric patients have not been established.
Dosing: Older adult
Geriatric use (US label) US FDA label
8.5 Geriatric Use No overall differences in safety or effectiveness have been observed between elderly and younger patients.
Dosage forms
Philippines
- Ophthalmic solution: 0.05 mg/mL, 50 mcg per mL, 50 mcg/mL
- Sterile ophthalmic solution: 50 mcg/mL
- Opthalmic solution: 50 mcg/mL
Registered products in the Philippines
18 products registered with the Food and Drug Administration (FDA) Philippines list Latanoprost as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
All registered products18
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
AstaproLatanoprost | 50 mcg/ mL (0.005% w/v) Ophthalmic SolutionIn 5 mL White LDPE Bottle x 2.5 mL with Dropper-undercap cap (Box of 1's) | Rx | Rafarm SAGreece | Aspen Philippines Inc.Trader: NTC SRL | DR-XY45556 | Dec 8, 2031 | |
IoprostLatanoprost | 50 mcg/mL (0.005% w/v) Ophthalmic Solution2.5 mL LDPE plastic bottle (Box of 1's) | Rx | ASHFORD PHARMACEUTICAL LABORATORIES, INC.Philippines | Trader: INNOVISION PHARMA INC. | DR-XY37905 | Jul 16, 2028 | |
LaprostLatanoprost | 0.05 mg/mL (0.005%) Ophthalmic Solution3 mL net content in 5 mL LDPE Opaque bottle /HDPE screw | Rx | Micro Labs LimitedIndia | Brown & Burk Philippines Inc. | DR-XY40933 | Jun 1, 2027 | |
LatadinLatanoprost | 50 mcg/mL (0.005% w/v) Sterile Ophthalmic Solution (Eye Drops)LDPE White Opaque Plastic Droptainer x 2.5 mL (Box of 1's) | Rx | Egyptian International Pharmaceutical Industries Co. (EIPICO)Egypt | Medchoice Vision Care Inc.Importer: Ambica International Corporation | DRP-8046-01 | Dec 5, 2028 | |
LatanoptaLatanoprost | 50 mcg/mL Ophthalmic Solution5 mL LDPE Container (natural) with LDPE Dropper (natural) and White HDPE Cap x 2.5 mL Box of 1’s | Rx | Beximco Pharmaceuticals Ltd.Bangladesh | Ambica International Corporation | DRP-10280 | Oct 10, 2029 | |
LatasoptLatanoprost | 0.005% Ophthalmic SolutionWhite LDPE Bottle covered by White HDPE Screw Cap with Safety Ring and White LDPE Dropper x 5mL (Box of 1's) | Rx | World Medicine İlaç Sanayi Ve Ticaret A.Ş.Türkiye | Pharma-Surrey International, Inc. | DRP-10594 | Oct 21, 2031 | |
LatochekLatanoprost | 50 mcg/mL (0.005% w/v) Ophthalmic Solution (Eye Drops)5 mL LDPE Bottle with LDPE Nozzle and White HDPE Cap (Net content: 2.5 mL) (Box of 1's) | Rx | Indoco Remedies LimitedIndia | Ambica International Corporation | DRP-9581 | Feb 26, 2031 | |
LatoprostLatanoprost | 50 mcg/mL (0.005% w/v) Ophthalmic SolutionLDPE Dropper Bottle x 5 mL | Rx | Sun Pharmaceutical Industries, Ltd.India | Sun Pharma Philippines, Inc. | DRP-8607 | Apr 11, 2028 | |
Latoprost RTLatanoprost | 50 mcg/mL (0.005% W/V) Ophthalmic Solution (Eye drops)5 mL LDPE Bottle x 2.5 mL (net content) (Box of 1's) | Rx | Sun Pharmaceutical Industries LimitedIndia | Sun Pharma Philippines, Inc. | DRP-8608 | Jan 4, 2038 | |
LprostLatanoprost | 50 mcg/mL (0.005% w/v) Ophthalmic Solution (Eye drops)5 mL-Capacity LDPE Plastic Bottle with LDPE Dropper and HDPE Tamper-evident Screw Cap x 2.5 mL (net content) (Box of 1's) | Rx | Joint Stock Company "Farmak"Ukraine | Suhitas Pharmaceuticals Inc. | DRP-13460 | Feb 23, 2028 | |
NoneLatanoprost | 50 mcg / mL Ophthalmic Solution5 mL LDPE Container (natural) with LDPE Dropper (natural) and White HDPE Cap x 2.5 mL (Box of 1's) | Rx | Beximco Pharmaceuticals Ltd.Bangladesh | Celsus Pharmaceuticals Phil., Inc.Importer: Ambica International Corporation | DRP-10280-01 | Oct 10, 2029 | |
NovaprostLatanoprost | 50 mcg/mL (0.005% w/v) Ophthalmic SolutionLDPE dropper bottle with HDPE cap x 8 mL (Box of 1's) | Rx | Pharmacos Exakta, S.A. de C.V.Mexico | Medinova Pharmaceutical Inc.Trader: Opko Health Spain S.L.U. | DRP-13583 | Mar 14, 2028 | |
OculatLatanoprost | 50 mcg/mL Opthalmic Solution2.5 mL (Net Content) in 5 mL White LDPE Plastic Bottle with Dropping Nozzle and PVC Cap Box of 1's | Rx | Remington Pharmaceutical industries (Pvt.) Ltd.Pakistan | Ophthamed Pharma Corp. | DRP-12204 | Jan 26, 2030 | |
OcupresLatanoprost | 50 mcg per mL Ophthalmic SolutionLDPE dropper bottle x 2.5 mL (Box of 1's) | OTC | Rafarm S.A.Greece | UNILAB, Inc. | DRP-16992 | Sep 4, 2030 | |
TanopLatanoprost | 50 mcg/mL (0.005% w/v) Ophthalmic Solution (Eye Drops)LDPE Vial x 2.5 mL (Box of 1's) | Rx | FDC LimitedIndia | Penta Labs Australia (Philippines) | DRP-6159 | Apr 22, 2030 | |
XalaprostLatanoprost | 50 mcg/mL (0.005% w/v) Ophthalmic Solution (Drops)2.5 mL in 5 mL-Capacity White Translucent LDPE Container (Natural) With LDPE Dropper (Natural) And HDPE Tamper-Evident White Screw Cap (Box of 1’s) | Rx | Beximco Pharmaceuticals Ltd.Bangladesh | Aglobal Care, Inc. | DR-XY47596 | Dec 9, 2031 | |
XalatanLatanoprost | 50 mcg/mL Ophthalmic Solution (Drops)Polyethylene container with Flexirene LMDPE dropper resin tip x 2.5 mL (Box of 1's) | Rx | Pfizer Manufacturing Belgium NVBelgium | Importer: Viatris, Inc. | DRP-16156 | Jun 19, 2037 | |
XalatrexLatanoprost | 50 mcg/mL (0.005 % w/v) Sterile Ophthalmic Solution (Eye Drops)LDPE White Opaque Plastic Droptainer x 2.5 mL (Box of 1's) | Rx | Egyptian International Pharmaceutical Industries Co. (EIPICO)Egypt | Sankem Healthcare Inc.Importer: Ambica International Corporation | DRP-8046 | Dec 5, 2028 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
United States (label)
Dosage forms and strengths (US label) US FDA label
3 DOSAGE FORMS AND STRENGTHS Ophthalmic solution containing latanoprost 50 mcg/mL (0.005%). Ophthalmic solution containing latanoprost 50 mcg/mL (0.005%). (3)
Warnings/Precautions
- • Pigmentation: Pigmentation of the iris, periorbital tissue (eyelid) and eyelashes can occur. Iris pigmentation likely to be permanent. (5.1)
- • Eyelash Changes: Gradual change to eyelashes including increased length, thickness and number of lashes. Usually reversible. (5.2)
5.1 Pigmentation
5.1 Pigmentation XALATAN has been reported to cause changes to pigmented tissues. The most frequently reported changes have been increased pigmentation of the iris, periorbital tissue (eyelid), and eyelashes. Pigmentation is expected to increase as long as latanoprost is administered. The pigmentation change is due to increased melanin content in the melanocytes rather than to an increase in the number of melanocytes.
After discontinuation of latanoprost, pigmentation of the iris is likely to be permanent, while pigmentation of the periorbital tissue and eyelash changes have been reported to be reversible in some patients. Patients who receive treatment should be informed of the possibility of increased pigmentation. Beyond 5 years the effects of increased pigmentation are not known [see Clinical Studies (14.2)].
Iris color change may not be noticeable for several months to years. Typically, the brown pigmentation around the pupil spreads concentrically towards the periphery of the iris and the entire iris or parts of the iris become more brownish. Neither nevi nor freckles of the iris appear to be affected by treatment. While treatment with XALATAN can be continued in patients who develop noticeably increased iris pigmentation, these patients should be examined regularly.
5.2 Eyelash Changes
5.2 Eyelash Changes XALATAN may gradually change eyelashes and vellus hair in the treated eye; these changes include increased length, thickness, pigmentation, the number of lashes or hairs, and misdirected growth of eyelashes. Eyelash changes are usually reversible upon discontinuation of treatment.
5.3 Intraocular Inflammation
5.3 Intraocular Inflammation XALATAN should be used with caution in patients with a history of intraocular inflammation (iritis/uveitis) and should generally not be used in patients with active intraocular inflammation because inflammation may be exacerbated.
5.4 Macular Edema
5.4 Macular Edema Macular edema, including cystoid macular edema, has been reported during treatment with XALATAN. XALATAN should be used with caution in aphakic patients, in pseudophakic patients with a torn posterior lens capsule, or in patients with known risk factors for macular edema.
5.5 Herpetic Keratitis
5.5 Herpetic Keratitis Reactivation of herpes simplex keratitis has been reported during treatment with XALATAN. XALATAN should be used with caution in patients with a history of herpetic keratitis. XALATAN should be avoided in cases of active herpes simplex keratitis because inflammation may be exacerbated.
5.6 Bacterial Keratitis
5.6 Bacterial Keratitis There have been reports of bacterial keratitis associated with the use of multiple-dose containers of topical ophthalmic products. These containers had been inadvertently contaminated by patients who, in most cases, had a concurrent corneal disease or a disruption of the ocular epithelial surface.
5.7 Contact Lens Use
5.7 Contact Lens Use XALATAN contains benzalkonium chloride, which may be absorbed by contact lenses. Contact lenses should be removed prior to the administration of XALATAN, and may be reinserted 15 minutes after administration.
Adverse reactions
The following adverse reactions were reported in postmarketing experience and are discussed in greater detail in other sections of the label:
- Iris pigmentation changes [see Warnings and Precautions (5.1)]
- Eyelid skin darkening [see Warnings and Precautions (5.1)]
- Eyelash changes (increased length, thickness, pigmentation, and number of lashes) [see Warnings and Precautions (5.2)]
- Intraocular inflammation (iritis/uveitis) [see Warnings and Precautions (5.3)]
- Macular edema, including cystoid macular edema [see Warnings and Precautions (5.4)] Most common adverse reactions (5-15%) from clinical trials are blurred vision, burning and stinging, conjunctival hyperemia, foreign body sensation, itching, increased pigmentation of the iris, and punctate keratitis. (6) To report SUSPECTED ADVERSE REACTIONS, contact Viatris at 1-877-446-3679 (1-877-4-INFO-RX) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
6.1 Clinical Trials Experience
6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, the adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. XALATAN was studied in three multicenter, randomized, controlled clinical trials.
Patients received 50 mcg/mL XALATAN once daily or 5 mg/mL active-comparator (timolol) twice daily. The patient population studied had a mean age of 65±10 years. Seven percent of patients withdrew before the 6-month endpoint. Table 1: Ocular Adverse Reactions and Ocular Signs/Symptoms Reported by 5-15% of Patients Receiving Latanoprost Symptom/Finding Adverse Reactions (Incidence (%)) Latanoprost (n=460) Timolol (n=369) Foreign body sensation 13 8 Punctate keratitis 10 9 Stinging 9 12 Conjunctival hyperemia 8 3 Blurred vision 8 8 Itching 8 8 Burning 7 8 Increased pigmentation of the iris 7 0 Less than 1% of the patients treated with XALATAN required discontinuation of therapy because of intolerance to conjunctival hyperemia.
Table 2: Adverse Reactions That Were Reported in 1-5% of Patients Receiving Latanoprost Adverse Reactions (Incidence (%)) Latanoprost (n=460) Timolol (n=369) Ocular Events/Signs and Symptoms Excessive tearing 4 6 Eyelid discomfort/pain 4 2 Dry eye 3 3 Eye pain 3 3 Eyelid margin crusting 3 3 Erythema of the eyelid 3 2 Photophobia 2 1 Eyelid edema 1 3 Blepharitis 1 3 Systemic Events Upper respiratory tract infection/nasopharyngitis/influenza 3 3 Myalgia/arthralgia/back pain 1 0.5 Rash/allergic skin reaction 1 0.3
6.2 Postmarketing Experience
6.2 Postmarketing Experience The following reactions have been identified during postmarketing use of XALATAN in clinical practice. Because they are reported voluntarily from a population of unknown size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. The reactions, which have been chosen for inclusion due to either their seriousness, frequency of reporting, possible causal connection to XALATAN, or a combination of these factors, include: Nervous System Disorders: Dizziness; headache; toxic epidermal necrolysis Eye Disorders: Eyelash and vellus hair changes of the eyelid (increased length, thickness, pigmentation, and number of eyelashes); keratitis; corneal edema and erosions; intraocular inflammation (iritis/uveitis); macular edema, including cystoid macular edema; trichiasis; periorbital and lid changes resulting in deepening of the eyelid sulcus; iris cyst; eyelid skin darkening; localized skin reaction on the eyelids; conjunctivitis; pseudopemphigoid of the ocular conjunctiva.
Respiratory, Thoracic and Mediastinal Disorders: Asthma and exacerbation of asthma; dyspnea Gastrointestinal Disorders: Nausea; vomiting Skin and Subcutaneous Tissue Disorders: Pruritis Infections and Infestations: Herpes keratitis Cardiac Disorders: Angina; palpitations; angina unstable General Disorders and Administration Site Conditions: Chest pain
Adverse reaction frequency tables (US label) US FDA label
| Symptom/Finding | Adverse Reactions (Incidence (%)) | |
| Latanoprost(n=460) | Timolol(n=369) | |
| Foreign body sensation | 13 | 8 |
| Punctate keratitis | 10 | 9 |
| Stinging | 9 | 12 |
| Conjunctival hyperemia | 8 | 3 |
| Blurred vision | 8 | 8 |
| Itching | 8 | 8 |
| Burning | 7 | 8 |
| Increased pigmentation of the iris | 7 | 0 |
| Adverse Reactions (Incidence (%)) | ||
| Latanoprost(n=460) | Timolol(n=369) | |
| Ocular Events/Signs and Symptoms | ||
| Excessive tearing | 4 | 6 |
| Eyelid discomfort/pain | 4 | 2 |
| Dry eye | 3 | 3 |
| Eye pain | 3 | 3 |
| Eyelid margin crusting | 3 | 3 |
| Erythema of the eyelid | 3 | 2 |
| Photophobia | 2 | 1 |
| Eyelid edema | 1 | 3 |
| Blepharitis | 1 | 3 |
| Systemic Events | ||
| Upper respiratory tract infection/nasopharyngitis/influenza | 3 | 3 |
| Myalgia/arthralgia/back pain | 1 | 0.5 |
| Rash/allergic skin reaction | 1 | 0.3 |
Pregnancy considerations
Pregnancy (US label) US FDA label
8.1 Pregnancy Risk Summary There are no adequate and well-controlled studies of XALATAN administration in pregnant women to inform drug-associated risks. In animal reproduction studies, intravenous (IV) administration of latanoprost to pregnant rabbits and rats throughout the period of organogenesis produced malformations, embryofetal lethality and spontaneous abortion at clinically relevant doses [see Data].
The background risk of major birth defects and miscarriage for the indicated population is unknown. However, the background risk in the U.S. general population of major birth defects is 2 to 4%, and of miscarriage is 15 to 20% of clinically recognized pregnancies. Data Animal Data Embryofetal studies were conducted in pregnant rabbits administered latanoprost daily by IV injection on gestation days 6 through 18, to target the period of organogenesis.
A no observed adverse effect level (NOAEL) was not established for rabbit developmental toxicity. Post-implantation loss due to late resorption was shown as doses ≥0.2 mcg/kg/day (equivalent to 1.3 times the maximum recommended human ophthalmic dose [RHOD], on a mg/m 2 basis, assuming 100% absorption). Spina bifida and abortion occurred at 5 mcg/kg/day (equivalent to 32 times the maximum RHOD).
Total litter loss due to early resorption was observed at doses ≥50 mcg/kg/day (324 times the maximum RHOD). Transient signs of maternal toxicity were observed after IV dosing (increased breathing, muscle tremors, slight motor incoordination) at 300 mcg/kg/day (1946 times the maximum RHOD). No maternal toxicity was observed at doses up to 50 mcg/kg/day.
Embryofetal studies were conducted in pregnant rats administered latanoprost daily by IV injection on gestation days 6 through 15, to target the period of organogenesis. A NOAEL for rat developmental toxicity was not established. Cleft palate was observed at 1 mcg/kg (equivalent to 3.2 times the maximum RHOD, on a mg/m 2 basis, assuming 100% absorption).
Brain porencephalic cyst(s) were observed ≥50 mcg/kg (162 times the maximum RHOD). Skeletal anomalies were observed at 250 mcg/kg (811 times the maximum RHOD). No maternal toxicity was detectable at 250 mcg/kg/day. Prenatal and postnatal development was assessed in rats. Pregnant rats were administered latanoprost daily by IV injection from gestation day 15, through delivery, until weaning (lactation day 21).
No adverse effects on rat offspring were observed at doses up to 10 mcg/kg/day (32 times the maximum RHOD, on a mg/m 2 basis, assuming 100% absorption). At 100 mcg/kg/day (324 times the maximum RHOD), maternal deaths and pup mortality occurred.
Mechanism of action
12.1 Mechanism of Action Latanoprost is a prostaglandin F 2α analogue that is believed to reduce the IOP by increasing the outflow of aqueous humor. Studies in animals and man suggest that the main mechanism of action is increased uveoscleral outflow. Elevated IOP represents a major risk factor for glaucomatous field loss. The higher the level of IOP, the greater the likelihood of optic nerve damage and visual field loss.
US FDA labelPharmacodynamics
Pharmacodynamics (US label) US FDA label
12.2 Pharmacodynamics Reduction of the IOP in man starts about 3-4 hours after administration and maximum effect is reached after 8-12 hours. IOP reduction is present for at least 24 hours.
Pharmacokinetics
Excretion The elimination of the acid of latanoprost from human plasma is rapid (t 1/2 = 17 min) after both IV and topical administration.
Pharmacokinetics (US label) US FDA label
12.3 Pharmacokinetics Absorption Latanoprost is absorbed through the cornea where the isopropyl ester prodrug is hydrolyzed to the acid form to become biologically active. Distribution The distribution volume in humans is 0.16±0.02 L/kg. The acid of latanoprost can be measured in aqueous humor during the first 4 hours, and in plasma only during the first hour after local administration.
Studies in man indicate that the peak concentration in the aqueous humor is reached about 2 hours after topical administration. Elimination Metabolism Latanoprost, an isopropyl ester prodrug, is hydrolyzed by esterases in the cornea to the biologically active acid. The active acid of latanoprost reaching the systemic circulation is primarily metabolized by the liver to the 1,2-dinor and 1,2,3,4-tetranor metabolites via fatty acid β-oxidation.
Excretion The elimination of the acid of latanoprost from human plasma is rapid (t 1/2 = 17 min) after both IV and topical administration. Systemic clearance is approximately 7 mL/min/kg. Following hepatic β-oxidation, the metabolites are mainly eliminated via the kidneys. Approximately 88% and 98% of the administered dose are recovered in the urine after topical and IV dosing, respectively.
Formulary and pricing (Philippines)
Government price references
| Preparation | Price (PHP) | Unit | Type |
|---|---|---|---|
| Latanoprost 50mcg/mL, 2.5mL Bottle | ₱500.00–₱1,056.00Reference ₱800.00 | per bottle | DPRI procurement range |
Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)
These are government procurement and reimbursement references, not retail prices. Sources:
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf, as of September 17, 2021
Formulary and coverage
| Philippine National Formulary | Listed as Latanoprost |
| PNF listing | Eye Drops Solution: 50 micrograms/mL, 2.5 mL bottle |
| PhilHealth GAMOT | No |
Sources:
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf, as of November 2, 2022
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- U.S. Food and Drug Administration. XALATAN · Viatris Specialty LLC [US FDA-approved label, version 2, May 15, 2023]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a98595b3-9f47-48e0-b18d-550a2095f264
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf
This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.
Last updated: .